Company

Q32 Bio Inc.

Cambridge-based Q32 Bio develops immune therapeutics for autoimmune and inflammatory diseases, led by bempikibart.

About

Founded in 2020 and headquartered in Cambridge, US, Q32 Bio Inc. develops immune therapeutics for autoimmune and inflammatory diseases. Its lead candidate, Bempikibart (ADX-914), is a fully human anti-IL-7Ra antagonist monoclonal antibody being evaluated in a Phase 2 program for alopecia areata. The company completed a MERGER with Homology Medicines, Inc. on November 16, 2023, raising USD 275.00 mn, and has raised USD 42.00 mn in total. It reported revenue of USD 1.156 mn in 2023, and the company was formed by Shelia Violette.

2Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in